Emergent BioSolutions (STU:ER4) Total Liabilities: €689.7 Mil (As of Mar. 2026)


STU:ER4 Emergent BioSolutions Inc STU:ER4
57 GF Score
Price €7.01
GF Value €4.10
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Total Liabilities?

Emergent BioSolutions STU:ER4 -0.85% 57 Total Liabilities is €689.7 Mil as of Mar. 2026. GuruFocus rates STU:ER4 with a GF Score™ of 57/100 and a GF Value™ of €4.10 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Emergent BioSolutions's Total Liabilities for the quarter that ended in Mar. 2026 was €689.7 Mil.

Emergent BioSolutions's quarterly Total Liabilities declined from Sep. 2025 (€748.48 Mil) to Dec. 2025 (€679.78 Mil) but then increased from Dec. 2025 (€679.78 Mil) to Mar. 2026 (€689.66 Mil).

Emergent BioSolutions's annual Total Liabilities declined from Dec. 2023 (€1,076.47 Mil) to Dec. 2024 (€866.09 Mil) and declined from Dec. 2024 (€866.09 Mil) to Dec. 2025 (€679.78 Mil).

Emergent BioSolutions Total Liabilities Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Total Liabilities Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,191.39 1,679.00 1,076.47 866.09 679.78

Emergent BioSolutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 807.90 763.74 748.48 679.78 689.66
STU:ER4
57GF Score
Emergent BioSolutions Inc STU:ER4
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Emergent BioSolutions's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=112.899+(488.573+46.031
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+32.281+0+0)
=679.8

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1126.084-446.3
=679.8

Emergent BioSolutions's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=128.625+(496.164+36.071
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+28.804+0+0)
=689.7

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1142.146-452.481
=689.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €689.7 Mil mean?
Emergent BioSolutions (STU:ER4) has a Total Liabilities of €689.7 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Total Liabilities too high?
Emergent BioSolutions' current Total Liabilities is €689.7 Mil. Overall, Emergent BioSolutions has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Total Liabilities compare to ELTP and NIKA?
Emergent BioSolutions' Total Liabilities of €689.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Emergent BioSolutions and its competitors. Emergent BioSolutions's current Total Liabilities is €689.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.10, compared to a current price of €7.01 — trading 71% above its estimated fair value. The current Total Liabilities is €689.7 Mil. Emergent BioSolutions' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current Total Liabilities is €689.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €7.01 is trading 71% above its estimated GF Value™ of €4.10. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for STU:ER4:

  • Total Liabilities: €689.7 Mil
  • GF Value™: €4.10 vs. price of €7.01 (71% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UK
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
57GF Score

Get the complete analysis for STU:ER4

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.01
Price
€4.10
GF Value